Business Context and Reporting Period
Company: Phio Pharmaceuticals Corp.
Filing Type: Form 8-K (Current Report)
Date of Report: November 19, 2019
Reporting Period: Events occurring on November 17 and November 18, 2019.
The filing details a registered public offering of common stock and a unilateral repricing of outstanding warrants to facilitate capital raising for the company's immuno-oncology program.
Key Financial Metrics
This filing does not contain standard periodic financial statements (e.g., revenue, net income, or operating cash flow). Key transaction-specific financial data includes:
- Shares Issued: 10,000,000 shares of Common Stock.
- Offering Price: $0.10 per share.
- Gross Proceeds: $1,000,000 (calculated from shares and price).
- Net Proceeds: Approximately $725,000 after deducting fees and expenses.
- Placement Agent Fees: 7.5% cash fee, 1.0% management fee, plus up to $40,000 for legal expenses and $10,000 for clearing expenses.
- Warrant Issuance: 750,000 Placement Agent Warrants issued (7.5% of shares sold) with an exercise price of $0.125 per share, expiring November 19, 2024.
- Warrant Repricing: Existing outstanding warrants (excluding pre-funded) repriced to an exercise price of $0.19 per share.
- Potential Future Proceeds: Up to $4.07 million if all repriced warrants are exercised.
Material Changes
The filing reports two material events:
- Capital Raise: Entry into a Placement Agency Agreement with H.C. Wainwright & Co., LLC to sell 10 million shares at $0.10 per share.
- Warrant Adjustment: Unilateral reduction of the exercise price of outstanding warrants to $0.19 per share, effective November 19, 2019, to align with the closing price of the stock on November 15, 2019.
Guidance, Outlook, and Risks
Use of Proceeds: The Company intends to use substantially all net proceeds for the development of its immuno-oncology program, other research and development activities, and general working capital.
Investor Conditions: Purchasers in the Offering were required to agree not to sell shares until November 19, 2019 (the record date for the next stockholder meeting) and to vote in favor of a reverse stock split amendment to the articles of incorporation.
Risks and Contingencies:
- There is no assurance that the repriced warrants will be exercised.
- The Offering was conducted pursuant to a shelf registration statement (Form S-3) declared effective in April 2018.
Investor Verification Checklist
- Verify the final closing date and actual net proceeds received versus the estimated $725,000.
- Confirm the status of the proposed reverse stock split amendment at the upcoming stockholder meeting.
- Review the full text of the Placement Agency Agreement (Exhibit 1.1) for specific termination provisions and representations.
- Monitor the exercise activity of the repriced warrants to assess potential future dilution or capital inflow.
- Check subsequent filings for updates on the immuno-oncology program development funded by this offering.